Lonza Signs Exclusive Agreement with Index Ventures for the Development and Manufacture of Biologics for Portfolio Companies

Lonza, a global leader in biological manufacturin,g and Index Ventures, LLP, a leading venture capital investment firm, have announced an exclusive agreement for process development and cGMP production for all biological products in the portfolio of companies where Index is the major investor.

During the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.

“This agreement shows that Lonza’s value to a company’s product development pipeline is being recognised more widely by investors in biotech companies,” said Dr Stephan Kutzer, COO Lonza Pharma&Biotech. “This multi-product agreement demonstrates Lonza’s ability to offer world-class expression platforms in combination with secure manufacturing capabilities for the complete product lifecycle.” 

Kevin Johnson, Partner at Index Ventures commented: “Lonza has manufactured the majority of the antibody products I’ve worked on in the last 20 years and proved to be an excellent partner. I’m pleased that we’re now able to extend that expertise to our asset-centric portfolio companies, enabling them to benefit as though they were much larger organisations.”